我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
10
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
已完成
4
40.0%
尚未招募
1
10.0%
Unknown
5
50.0%
暂无批准数据
- Microbio's postbiotic MS-20 achieved 83.3% clinical remission rate in ulcerative colitis patients when added to standard treatments, compared to 35.7% with placebo, demonstrating statistically significant improvement (p=0.021). - The treatment showed rapid efficacy with 58.3% of MS-20 patients achieving clinical remission by week 4, versus just 7.1% in the placebo group, potentially allowing patients to resume normal activities sooner. - MS-20, developed through symbiotic fermentation of multi-strain probiotics, works by reshaping gut microbiota, repairing epithelial barriers, and suppressing intestinal inflammation, addressing limitations of conventional UC therapies.
